Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NervGen Pharma Corp. (V:NGEN)

Business Focus: Biotechnology & Medical Research

Oct 04, 2021 08:30 am ET
U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury
Cincinnati, Ohio--(Newsfile Corp. - October 4, 2021) - NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the United States Senate Armed Services Committee for its release of the Fiscal Year 2022 National Defense Authorization Act (FY 22 NDAA) and the accompanying report language related to traumatic brain injury (TBI).
Sep 27, 2021 08:30 am ET
NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a partnership with Imeka Solutions Inc. ("Imeka"), currently the only neuroimaging company that combines artificial intelligence and diffusion imaging to obtain high resolution images of white matter in the brain. NervGen intends to utilize Imeka's imaging technology as a sensitive pharmacodynamic biomarker for its lead compound, NVG-291, in its Phase 1b/2 clinical trials. Additionally, the companies are submitting non-dilutive grants that support combining their technologies in preclinical and clinical studies for various conditions related to central nervous system damage.
Sep 14, 2021 07:03 pm ET
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Directors exercisable at a price of $2.10 per share for a period of five years with vesting that is either time or performance based. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.
Sep 13, 2021 09:00 am ET
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF). The full research publication can be found on our website at www.encodelp.com, or by clicking here.
Sep 12, 2021 04:45 pm ET
NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.
Sep 10, 2021 08:30 am ET
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 9, 2021.
Aug 19, 2021 08:30 am ET
NervGen Pharma Provides an Operational Update on Its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial results for the second quarter ended June 30, 2021.
Aug 09, 2021 08:30 am ET
NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease
Dr. Ksenia Kastanenka to Study NVG-291's Potential to Promote Repair in Alzheimer's Disease Models
Aug 05, 2021 08:30 am ET
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Jul 16, 2021 07:52 pm ET
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisable at $2.00 per share for a period of three years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.
Jul 15, 2021 08:30 am ET
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board
NervGen Supports World Brain Day on July 22 to "Stop Multiple Sclerosis"
Jul 12, 2021 08:30 am ET
NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer's Disease Scientific Advisory Board. Drs. Martin Farlow, Reisa Sperling and Michael Weiner have agreed to join Drs. Jeffrey Cummings, Bruce Lamb, George Perry and Henrik Zetterberg on the Alzheimer's Disease Scientific Advisory Board to guide NervGen as it prepares for the Phase 1b clinical trial of its lead compound, NVG-291, in Alzheimer's patients that is slated to begin in 2022.
Jun 25, 2021 05:00 pm ET
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it has engaged Vorticom Inc. ("Vorticom"), a New York based full-service public relations agency to provide media relations and related services for the Company.
Jun 10, 2021 08:30 am ET
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease
May 20, 2021 08:30 am ET
NervGen Pharma Reports First Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021.
May 12, 2021 09:01 am ET
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, announced that it has closed its previously announced overnight, "best efforts" marketed public offering (the "Offering") of units (the "Units"). Pursuant to the Offering, NervGen issued an aggregate of 3,250,000 units of the Company at a price of C$1.55 per Unit for aggregate gross proceeds of C$5,037,500. Each Unit is comprised of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable at a price of C$2.10 and entitles the holder thereof to acquire one common share of the Company for a period of 2 years following the closing of the Offering.
May 07, 2021 07:26 pm ET
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted 800,000 incentive stock options to an Officer of the Company exercisable at a price of $1.51 per share for a period of 10 years and that vest equally every six months over a two-year period. The options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.
May 06, 2021 08:30 am ET
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the Company's Phase 1 clinical trial in healthy volunteers.
May 05, 2021 12:05 pm ET
IIROC Trading Resumption - NGEN
VANCOUVER, BC, May 5, 2021 /CNW/ - Trading resumes in:
May 05, 2021 11:42 am ET
NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has priced its previously announced overnight, "best efforts" marketed public offering (the "Offering") of units (the "Units"). Pursuant to the Offering, NervGen will issue an aggregate of up to 3.25 million units of the Company at a price of C$1.55 per Unit for aggregate gross proceeds of up to approximately C$5 million. Each Unit is comprised of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable at a price of C$2.10 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share") for a period of 2 years following the closing of the Offering.
May 05, 2021 09:16 am ET
IIROC Trading Halt - NGEN
VANCOUVER, BC, May 5, 2021 /CNW/ - The following issues have been halted by IIROC:
May 04, 2021 04:41 pm ET
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has launched an overnight, "best efforts" marketed public offering (the "Offering") of units (the "Units"), each Unit being comprised of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market.
Apr 23, 2021 07:15 pm ET
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 306,000 incentive stock options to Employees and Officers exercisable at a price of $1.65 per share for a period of 10 years and that vest equally every six months over a two-year period. In addition, 175,000 incentive stock options were granted to consultants exercisable at a price of $1.65 per share for a period of three to five years and that vest equally either every three months over a one-year period or each month over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.
Apr 22, 2021 08:30 am ET
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce the appointment of Daniel Mikol, MD, PhD, as the Company's Chief Medical Officer, effective May 5th, 2021. Dr. Mikol, who currently holds the position of Executive Medical Director, Global Clinical Development at Amgen, will oversee NervGen's medical and clinical activities, with a primary focus on NervGen's lead product, NVG-291, which is initially being developed to treat multiple sclerosis, Alzheimer's disease and spinal cord injury.
Apr 14, 2021 08:30 am ET
Apr 08, 2021 04:30 pm ET
NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.
Mar 08, 2021 08:30 am ET
NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan Designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor. This new EMA designation provides NervGen with multiple incentives, including improved access to scientific advice, fee reductions, and 10 years of protection from market competition in Europe from similar medicines with similar indications following the date that the drug candidate receives marketing authorization (called market exclusivity).
Mar 04, 2021 08:30 am ET
NervGen Pharma Provides Regulatory Update on Development Program For NVG-291
Plans to Dose First Human Subjects in Phase 1 in Q2 2021
Jan 27, 2021 08:30 am ET
NervGen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will add an Alzheimer's disease patient cohort to its Phase 1 clinical trial program for its lead product, NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor.
Jan 26, 2021 08:30 am ET
NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer's Disease Scientific Advisory Board ("AD-SAB") with the appointment of four world-class scientists and clinical researchers in Alzheimer's disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies.
Jan 05, 2021 08:30 am ET
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6, 2021 at 3:00pm Eastern Time.
Dec 15, 2020 08:30 am ET
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited ("Novotech"), a leading full-service contract research organization ("CRO") in Asia-Pacific, for its upcoming Phase 1 clinical trial for NVG-291. NervGen currently plans to initiate its Phase 1 clinical trial in Australia starting in Q1 2021.
Nov 19, 2020 08:30 am ET
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020.
Nov 10, 2020 08:30 am ET
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer's Disease Program and Renews Business Advisory Relationship with Brian McAlister
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer's Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio, to provide independent, expert and multi-disciplinary strategic advice to guide the development of the Company's lead compound, NVG-291, in the treatment of Alzheimer's disease. NervGen is also pleased to announce that Brian McAlister, NervGen co-founder, has agreed to extend his engagement as a strategic advisor with the Company for an additional two years.
Oct 28, 2020 08:30 am ET
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company's Board of Directors. Separately, NervGen announced that they were advised by its clinical research organization of a logistical delay in obtaining certain materials that are necessary to complete the analysis of their ongoing non-clinical studies. The results of these studies are required prior to initiating the Phase 1 trial; therefore, the Company has revised its guidance for the start of its Phase 1 study from Q4 2020 to Q1 2021.
Oct 19, 2020 08:30 am ET
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-Dilutive Funding Sources For NVG-291
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly Director of the U.S. Combat Casualty Care Research Program, to help NervGen identify, prioritize and secure sources of non-dilutive funding for developing its lead compound, NVG-291, for treating nerve damage.
Oct 01, 2020 07:56 pm ET
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury and Alzheimer's disease. The NVG-291 development program is planned as follows:
Sep 22, 2020 05:26 pm ET
NervGen Pharma Announces Annual General Meeting and Company Update to Be Held on September 30, 2020
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholders (the "AGM") on Wednesday, September 30, 2020 at 2:00 p.m. PDT, as previously advised in the Company's Notice of Meeting filed with the Canadian securities regulatory authorities and posted on SEDAR on September 2, 2020.
Sep 10, 2020 08:30 am ET
NervGen Pharma Announces Departure of Chief Operating Officer
LifeSci Advisors Engaged to Provide Investor Relations Services
Aug 21, 2020 08:30 am ET
NervGen Pharma Reports Second Quarter 2020 Results
Phase 1 Clinical Study Remains on Track for Q4 2020
Aug 10, 2020 09:13 am ET
NervGen Pharma Corp. Completes $6.45 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that today it has closed its previously announced "best efforts" public offering of 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of $6,450,000 (the "Offering"). The Offering was led by Haywood Securities Inc. ("Haywood") who acted as sole agent and bookrunner. Brookline Capital Markets, a division of Arcadia Securities LLC, was the lead United States placement agent, acting as a member of the selling group.
Aug 04, 2020 08:30 am ET
NervGen Pharma Corp. Announces Upsizing of Financing and Filing of Amended and Restated Prospectus Supplement
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that it has increased the size of its previously announced common share offering. The Company intends to issue up to 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of up to $6.45 million (the "Offering"). The Company has agreed with the Agents that the books are now closed and they are no longer soliciting new subscribers for this Offering.
Jul 30, 2020 08:30 am ET
NervGen Pharma Corp. Announces Filing of Prospectus Supplement
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announces that the Company has filed a prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated January 2, 2020 (the "Base Shelf Prospectus") in connection with its previously announced 'best efforts" public offering of up to 3,142,857 units of the Company (the "Units") at a price of $1.75 per Unit for aggregate gross proceeds of up to $5,500,000 (the "Offering").
Jul 27, 2020 08:30 am ET
NervGen Pharma Announces Pricing of Public Offering
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has priced its previously announced offering of equity securities (the "Offering"). Pursuant to the Offering, NervGen intends to issue units of the Company (the "Units") at a price of $1.75 per Unit.
Jul 22, 2020 04:42 pm ET
NervGen Pharma Corp. Announces Public Offering
NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce a “best efforts”...
Jun 22, 2020 08:15 am ET
NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
Ohio Department of Higher Education Awards $250,000 Grant To Dr. Jerry Silver, Co-inventor of NervGen's Lead Compound
Jun 03, 2020 04:30 pm ET
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock options to Directors, Officers and consultants exercisable at a price of $2.70 per share for a period of five years and that vest equally every three months over a one-year period. In addition, 40,000 incentive stock options were granted to employees exercisable at a price of $2.70 per share for a period of 10 years and that vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.
Jun 01, 2020 04:43 pm ET
NervGen Pharma Reports First Quarter 2020 Results
Phase 1 Clinical Trial Remains on Track for Q4 2020
May 20, 2020 04:13 pm ET
NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of 1,806,827 units of the Company at a price of CAD$1.25 per unit, for aggregate gross proceeds to the Company of CAD$2,258,534.
Apr 29, 2020 05:47 pm ET
NervGen Pharma Reports 2019 Year End Results
Phase 1 Clinical Study Remains on Track for Q4 2020
Feb 26, 2020 06:00 pm ET
NervGen Pharma Provides a Development Update on Its Lead Product NVG-291
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These changes are the result of a number of factors, including feedback from the United States Food and Drug Administration (the "FDA") on the recently submitted Investigational New Drug ("IND") application and a management review of the best pathways forward for demonstrating proof of concept in clinical studies. The update to the program is as follows:
Feb 24, 2020 08:00 am ET
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of Chief Financial Officer effective immediately. Mr. Adams replaces Mr. Robert Pilz who will continue to formally support the Company as a consultant.
Jan 13, 2020 10:53 am ET
NervGen Pharma Responds to Recent Increase in Market Activity
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material change in the Company's operations that would account for the recent increase in market activity.
Nov 27, 2019 08:00 am ET
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer
Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer
Nov 21, 2019 08:30 am ET
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has issued 1,500,000 common shares (the "Common Share(s)") to its manufacturing partner, CSBio, as partial consideration for an order of NVG-291 that will be used in the Company's clinical development programs (the "Transaction"). No proceeds were raised from the Transaction.
Nov 18, 2019 08:30 am ET
NervGen Pharma Receives Investment from Drug Manufacturing Partner
CSBio Invests US$1,500,000 as Part of Manufacturing Contract for Clinical Trial Product
Oct 28, 2019 08:30 am ET
NervGen Pharma Expands Platform into Alzheimer's Disease
NervGen Pharma's NVG-291 Compound on Track to Begin Phase 1 in Q1 2020
Sep 06, 2019 08:30 am ET
Jul 15, 2019 08:35 am ET
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 15, 2019 08:35 am ET
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
NEW YORK, July 15, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11th life sciences conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Jul 10, 2019 09:00 am ET
NervGen Pharma's Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen's core Intracellular Sigma Peptide ("ISP") technology in a mouse model representative of demyelination in multiple sclerosis.
Jul 09, 2019 12:03 pm ET
Life Science Company Live Investor Conference July 11th
NEW YORK, July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, July 11th.
Jul 09, 2019 12:00 pm ET
Life Science Company Live Investor Conference July 11th
Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jul 09, 2019 10:52 am ET
NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th
VANCOUVER, British Columbia, July 9, 2019 /PRNewswire/ -- NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Ernest Wong, President and CEO, will present live at VirtualInvestorConferences.com on July 11th.
Jul 05, 2019 05:00 pm ET
NervGen Amends Investor Relations Agreement
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of an investor relations services agreement dated January 16, 2019 with Mr. Huitt Tracey of Vancouver, Canada.
Jun 26, 2019 09:00 am ET
NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination
LeadIndication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial
Jun 10, 2019 07:00 am ET
NervGen Pharma Announces Upgrade to the OTCQX Best Market in the U.S.
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares on the OTCQX® Best Market ("OTCQX"). NervGen upgraded to OTCQX from the OTCQB® Venture Market and begins trading today under the symbol "NGENF".
Jun 04, 2019 03:30 pm ET
NervGen Pharma Presenting at the 9th Annual LD Micro Invitational
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma's President & CEO, will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5 at 8:40AM PDT / 11:40AM EDT. In addition, NervGen representatives will be available for investor meetings during the event.
Jun 03, 2019 08:30 am ET
NervGen Pharma Engages Torrey Hills Capital for Investor Relations
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San Diego based Torrey Hills Capital, Inc. ("Torrey Hills Capital") to provide market awareness and investor relations services to the Company.
May 30, 2019 09:00 am ET
NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing
Paul Brennan Joins NervGen Pharma as Business Advisor
May 03, 2019 09:00 am ET
NervGen Pharma Commences Trading on OTCQB
NervGen Pharma Engages Market Maker
May 02, 2019 10:59 am ET
NervGen Pharma Corp. Opens the Market
TORONTO, May 2, 2019 /CNW/ - Bill Radvak, Executive Chairman, NervGen Pharma Corp. (NGEN), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. NervGen is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. NervGen Pharma Corp. commenced trading on TSX Venture Exchange on March 13, 2019.
May 01, 2019 02:26 pm ET
Apr 24, 2019 09:00 am ET
NervGen Pharma's Patent Estate Grows with the Addition of US Patents for Its Groundbreaking Nerve Regeneration Technology
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - NervGen Pharma Corp. ("NervGen"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTPσ) targeted therapies for heart diseases and injury, and for root avulsion involving injuries into the peripheral nerve system.
Apr 23, 2019 06:08 pm ET
Amended: NervGen Pharma Increases Private Placement to $740,000
This Supersedes April 22, 2019 News Release
Apr 22, 2019 04:02 pm ET
NervGen Pharma Increases Private Placement to $650,000
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $650,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) and 300,000 shares at $1.30 each (new).
Apr 01, 2019 08:30 am ET
NervGen Pharma Appoints Amy Franke as VP, Clinical Operations
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Amy Franke as the Company's Vice President, Clinical Operations.
Mar 21, 2019 07:03 am ET
(PODCAST) NewlyTrading! NervGen Pharma Corp. (TSX.V:NGEN)
March 21 2019 / TheNewswire / On this edition of NewlyTrading, Dr. Ernest Wong, CEO of NervGen Pharma Corp. (TSX.V:NGEN).
Mar 14, 2019 05:08 pm ET
IIROC Trading Resumption - TR; NGEN; ALAB.P
VANCOUVER, March 14, 2019 /CNW/ - Trading resumes in:
Mar 14, 2019 01:03 am ET
NervGen Pharma Announces $500,000 Private Placement
Vancouver, Canada / TheNewswire / March 14, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it intends to complete a non-brokered private placement raising up to $500,000 through the issuance of up to 500,000 shares at $1.00 each.
Mar 13, 2019 03:52 pm ET
NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 - Symbol "NGEN"
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering ("IPO") of its common shares and listing as a Tier 2 company on the TSX Venture Exchange ("TSX-V").
Mar 13, 2019 07:56 am ET
IIROC Trading Halt - ALAB.P; NGEN
VANCOUVER, March 13, 2019 /CNW/ - The following issues have been halted by IIROC: